辨证论治联合重组人生长激素治疗矮小症临床研究  

Clinical Study on Syndrome Differentiation Combined with Recombinant Human Growth Hormone in the Treatment of Dwarfism

作　　者：石星磊 SHI Xinglei(不详)

机构地区：[1]遂昌县人民医院儿科,浙江遂昌323000

出　　处：《新中医》2021年第1期98-100,共3页New Chinese Medicine

摘　　要：目的:观察辨证论治联合重组人生长激素治疗矮小症患儿的临床疗效,并对其安全性进行分析。方法:将82例特发性矮小症患儿纳为本研究对象,通过随机分组将患儿分为观察组与对照组各41例。对照组接受常规治疗,观察组接受辨证论治联合重组人生长激素治疗,治疗时间持续1年。对比2组生长速率、骨龄增加速率以及并发症发生率间的差异。结果:观察组生长速率及骨龄增加速率均高于对照组,差异有统计学意义(P<0.05)。观察组并发症发生率为4.88%,低于对照组29.27%,差异有统计学意义(P<0.05)。结论:辨证论治联合重组人生长激素治疗矮小症患儿的临床疗效显著,安全性能较高。Objective:To observe the clinical effect of syndrome differentiation combined with recombinant human growth hormone in the treatment of children with dwarfism,and to analyze its safety.Methods:A total of 82 children with idiopathic dwarfism were randomly divided into the observation group and the control group,41 cases in each group.The control group received conventional treatment,and the observation group received treatment based on syndrome differentiation combined with recombinant human growth hormone.The treatment lasted for one year.The differences of growth rate,bone age increase rate and complication rate were compared between the two groups.Results:The growth rate and bone age increase rate in the observation group were higher than those in the control group,the difference being significant(P<0.05).The complication rate was 4.88%in the observation group,lower than that of 29.27%in the control group the difference being significant(P<0.05).Conclusion:Syndrome differentiation combined with recombinant human growth hormone has significant therapeutic effect in treating children with dwarfism with great safety.

关 键 词：特发性矮小症 辨证论治 重组人生长激素 并发症 安全性 

分 类 号：R725[医药卫生—儿科]